All News

2020

February

Media Release / Feb 17, 2020

Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide

Read More
Media Release / Feb 11, 2020

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

Read More

January

Media Release / Jan 31, 2020

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines

Read More
Media Release / Jan 31, 2020

Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis

Read More
Media Release / Jan 29, 2020

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

Read More
Media Release / Jan 20, 2020

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

Read More
Media Release / Jan 09, 2020

Novartis ligelizumab (QGE031) more effective than Xolair® at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria

Read More
Media Release / Jan 06, 2020

Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran

Read More
Media Release / Jan 06, 2020

Novartis completes tender offer for all outstanding shares of The Medicines Company

Read More
2019

December

Media Release / Dec 16, 2019

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More